financetom
Business
financetom
/
Business
/
Update: Market Chatter: DLocal Weighing Potential Sale, Other Options
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Market Chatter: DLocal Weighing Potential Sale, Other Options
Dec 18, 2024 9:49 AM

12:24 PM EST, 12/18/2024 (MT Newswires) -- (Updates to add DLocal's ( DLO ) response in the fourth paragraph and recent stock price movement in the fifth paragraph.)

DLocal ( DLO ) is exploring a potential sale, among other options, Reuters reported Wednesday, citing unnamed people familiar with the matter.

The Latin American payments provider is working with Morgan Stanley to assess takeover interest from potential suitors, including private-equity firms and large financial technology providers, the sources told the news agency.

DLocal ( DLO ) and Morgan Stanley declined to comment, Reuters reported.

DLocal ( DLO ) also declined to comment to MT Newswires, while Morgan Stanley did not immediately respond to a request for comment.

DLocal ( DLO ) shares were up 3.7% in recent trading.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 12.48, Change: +0.45, Percent Change: +3.70

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ARS Pharmaceuticals' Neffy Nasal Spray Approved by FDA for Type I Allergic Reactions
ARS Pharmaceuticals' Neffy Nasal Spray Approved by FDA for Type I Allergic Reactions
Aug 9, 2024
01:42 PM EDT, 08/09/2024 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) said Friday that the US Food and Drug Administration has approved neffy 2 mg, an epinephrine nasal spray, to treat Type I allergic reactions, including anaphylaxis, in adults and children weighing at least 30 kilograms. In a statement, the FDA said neffy is the first approved epinephrine product...
Turtle Beach Positioned for Growth Amid New Gaming Accessory Cycle, Oppenheimer Says
Turtle Beach Positioned for Growth Amid New Gaming Accessory Cycle, Oppenheimer Says
Aug 9, 2024
01:43 PM EDT, 08/09/2024 (MT Newswires) -- Turtle Beach ( HEAR ) is set for share gains and profitable growth as it enters a new gaming accessory cycle, Oppenheimer said in a note Friday. The company posted Q2 revenue of $76.5 million and adjusted earnings before interest, taxes, depreciation and amortization of $3 million, versus the consensus of $70.7 million...
--Stellantis Warns Union of Thousands of Potential Job Cuts at Detroit Plant, Associated Press Reports
--Stellantis Warns Union of Thousands of Potential Job Cuts at Detroit Plant, Associated Press Reports
Aug 9, 2024
01:45 PM EDT, 08/09/2024 (MT Newswires) -- Price: 15.37, Change: -0.15, Percent Change: -1.00 ...
YETI's Long-Term Growth Potential Shines: BofA Analyst Predicts Major Gains from Global Expansion and M&A
YETI's Long-Term Growth Potential Shines: BofA Analyst Predicts Major Gains from Global Expansion and M&A
Aug 9, 2024
YETI Holdings, Inc. ( YETI ) shares are trading lower Friday. BofA Securities analyst Alexander Perry upgraded the company to Buy (from Neutral) and raised the price target to $55 (from $46). The company reported second-quarter financial results yesterday and raised FY24 adjusted EPS guidance. YETI reported adjusted EPS of $0.70 (+23% Y/Y), beating the estimate. The company projects FY24 adjusted...
Copyright 2023-2026 - www.financetom.com All Rights Reserved